about
A code for RanGDP binding in ankyrin repeats defines a nuclear import pathwayA new crystal form of Lys48-linked diubiquitinHalogen bonds form the basis for selective P-TEFb inhibition by DRBThe CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor bComparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding modeAn inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states.Identification and Characterization of an Irreversible Inhibitor of CDK2.Recent developments in cyclin-dependent kinase biochemical and structural studies.MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.The ubiquitin-associated (UBA) 1 domain of Schizosaccharomyces pombe Rhp23 is essential for the recognition of ubiquitin-proteasome system substrates both in vitro and in vivoDifferential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System.Structure-based discovery of cyclin-dependent protein kinase inhibitors.Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach.Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.Structural insights into the functional diversity of the CDK-cyclin familyDifferences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK InhibitionFragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit GenerationIdentification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4
P50
Q24298137-153E898E-8FD7-423E-B1E3-0CCE373B3BADQ27664319-CA791DD3-FE70-4E0A-B904-B080928CF975Q27664568-14E7AE01-8E42-49CD-BB11-FE599EF0EB37Q27672752-46597C81-01B2-4181-914B-AE48E29DAB3DQ27675539-D92A1ACC-14F9-4424-95B7-E15F282A2F3CQ27687812-2E2B1D9D-5D2A-46C9-95AA-6EB411CAB85EQ33797218-2D4F7D2E-3180-4E14-B987-B89202F1A19AQ35759866-F94525E9-A1CB-4F35-8346-9F4357CB51D7Q37613187-500015B8-D2B5-45BC-A55F-3CA38D028DEDQ39482583-572D9625-801C-40F6-9749-01E84C6764B4Q40030976-CAC81550-6DC6-46DF-B88D-8650F4F371C6Q41890812-746CABDC-216E-4C62-A921-0A681EA8CC66Q45737789-2B21678A-96EF-4149-936A-F94B84F16E8FQ47423882-C6B007AF-497E-473A-9659-F3B2CE5518EAQ48124327-5670FCA2-41D3-4F04-B916-E920A601555CQ52690769-D2823BC5-AC9B-4024-B735-AB96076CB87DQ53790797-91037AE2-714D-4134-B0E6-8FF091AD9654Q58762403-E6C41635-C107-4B8B-835A-309BC2055171Q60017679-0EA17F25-5421-4F55-873D-A99B8FEC5AE5Q92295393-20BC66DC-85A0-411E-80CF-2105A09D0D03Q92849862-A25C41EC-3280-4452-B9BE-1461E7A2D226
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Jane A Endicott
@en
Jane A Endicott
@nl
type
label
Jane A Endicott
@en
Jane A Endicott
@nl
prefLabel
Jane A Endicott
@en
Jane A Endicott
@nl
P31
P496
0000-0003-4868-0116